US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Propanc Biopharma, Inc.

1.16

+0.07506.94%

Pre-market: 1.05-0.1050-9.09%05:23 EDT

Volume:23.01K

Turnover:26.23K

Market Cap:2.63M

PE:-0.04

High:1.19

Open:1.10

Low:1.08

Close:1.08

52wk High:85.50

52wk Low:0.9500

Shares:2.28M

Float Shares:269.40K

Volume Ratio:0.71

T/O Rate:8.54%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-32.4560

EPS(LYR):-371.2241

ROE:-126.98%

ROA:-62.31%

PB:0.27

PE(LYR):0.00

Loading ...

Overview Company News Filings

Propanc Biopharma plans 1-for-10 to 1-for-30 reverse stock split

Propanc Biopharma signs multi-year collaboration with Spanish universities

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration With the Universities of JaÉN and Granada, Spain

THOMSON REUTERS

Propanc Biopharma Inc. Files Draft Information Statement on Form PRE 14C

Propanc Biopharma Inc - Advancing Prp for Clinical Development in Pancreatic and Ovarian Cancers as Initial Priorities

THOMSON REUTERS

Propanc Biopharma Inc - Prp Demonstrates Over 85% Tumor Growth Inhibition in Preclinical Pancreatic Models

THOMSON REUTERS

Propanc Biopharma Inc - Phase 1B First-in-Human Trials for Prp Set for 2026; $100 Mln Facility in Place

THOMSON REUTERS

Propanc Biopharma executes service agreement with FyoniBio

Propanc Biopharma signs service agreement with FyoniBio for LC-MS pharmacokinetics assay validation

Propanc Biopharma Executes Service Agreement With Fyonibio to Establish & Validate Pharmacokinetics Assay for Phase 1B First-in-Human Study

THOMSON REUTERS

Propanc Biopharma highlights potential of lead asset PRP

BRIEF-Propanc Biopharma’S Lead Asset Prp Shows >85% Tumor Growth Inhibition In Preclinical Pancreatic Models

Propanc Biopharma Inc: Gearing up for a Phase 1B First-in-Human Trial in 2026

THOMSON REUTERS

Propanc Biopharma’s Lead Asset PRP Shows >85% TUMOR GROWTH INHIBITION IN PRECLINICAL PANCREATIC MODELS

THOMSON REUTERS

Propanc Biopharma Plans 2026 Phase 1b First-in-Human Trial for PRP in Advanced Solid Tumors

Propanc Biopharma Names Ralf Brant to Board as Julian Kenyon Retires

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/PPCB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":1.155,"timestamp":1787601600000,"preClose":1.08,"halted":0,"volume":23011,"hourTrading":{"tag":"盘前","latestPrice":1.05,"preClose":1.155,"latestTime":"05:23 EDT","volume":4288,"amount":4909.617209599999,"timestamp":1787649807547,"change":-0.105,"changeRate":-0.090909,"amplitude":0.087013},"delay":0,"changeRate":0.06944444444444439,"floatShares":269400,"shares":2278372,"eps":-32.455997,"marketStatus":"Pre-Mkt","change":0.075,"latestTime":"08-25 05:38:46 EDT","open":1.1,"high":1.19,"low":1.08,"amount":26228.934176299997,"amplitude":0.101852,"askPrice":1.28,"askSize":200,"bidPrice":0.9786,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-32.455997,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":1.155,"preHourTrading":{"tag":"盘前","latestPrice":1.05,"preClose":1.155,"latestTime":"05:23 EDT","volume":4288,"amount":4909.617209599999,"timestamp":1787649807547,"change":-0.105,"changeRate":-0.090909,"amplitude":0.087013},"postHourTrading":{"tag":"盘后","latestPrice":1.1322,"preClose":1.155,"latestTime":"19:59 EDT","volume":181,"amount":205.5822,"timestamp":1787615970622,"change":-0.0228,"changeRate":-0.01974,"amplitude":0.01974},"volumeRatio":0.7077676118295279},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":269400,"roa":"-62.31%","roe":"-126.98%","lyrEps":-371.224075,"volumeRatio":0.7077676118295279,"shares":2278372,"dividePrice":0,"high":1.19,"amplitude":0.101852,"preClose":1.08,"low":1.08,"week52Low":0.95,"pbRate":"0.27","week52High":85.495,"institutionHeld":0,"latestPrice":1.155,"committee":-0.333333,"eps":-32.455997,"divideRate":0,"volume":23011,"delay":0,"ttmEps":-32.455997,"open":1.1,"prevYearClose":13.415,"prevWeekClose":1.08,"prevMonthClose":1.01,"prevQuarterClose":1.5,"fiveDayClose":1.15,"twentyDayClose":1.32,"sixtyDayClose":1.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-18","symbol":"PPCB","defaultRemindTime":1779111000000,"type":"split","dateTimestamp":1779076800000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2026-08-21","current":-0.035587,"percent":0.474708,"low":-1.336323,"twenty":-0.295156,"median":-0.123158,"eighty":-0.040781,"high":-0.023125,"avg":-0.183178,"sd":0.195775,"marketCap":2506208},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660},{"date":"2025-10-24","current":-0.321672,"twenty":-0.645772,"median":-0.432247,"eighty":-0.369488,"marketCap":18953985},{"date":"2025-10-31","current":-0.269509,"twenty":-0.610693,"median":-0.4245,"eighty":-0.343407,"marketCap":15880366},{"date":"2025-11-07","current":-0.241906,"twenty":-0.556142,"median":-0.418378,"eighty":-0.313847,"marketCap":14253909},{"date":"2025-11-14","current":-0.169965,"twenty":-0.518234,"median":-0.404264,"eighty":-0.269509,"marketCap":10014876},{"date":"2025-11-21","current":-0.174454,"twenty":-0.514536,"median":-0.397743,"eighty":-0.234995,"marketCap":11061584},{"date":"2025-11-28","current":-0.188344,"twenty":-0.512687,"median":-0.384703,"eighty":-0.189884,"marketCap":11942288},{"date":"2025-12-05","current":-0.173885,"twenty":-0.509912,"median":-0.372748,"eighty":-0.182127,"marketCap":11025501},{"date":"2025-12-12","current":-0.170028,"twenty":-0.504827,"median":-0.356448,"eighty":-0.174606,"marketCap":10780935},{"date":"2025-12-19","current":-0.151754,"twenty":-0.498818,"median":-0.343407,"eighty":-0.171335,"marketCap":9622255},{"date":"2025-12-26","current":-0.139108,"twenty":-0.496968,"median":-0.326019,"eighty":-0.170682,"marketCap":8820401},{"date":"2026-01-02","current":-0.113099,"twenty":-0.476627,"median":-0.315152,"eighty":-0.168873,"marketCap":7171266},{"date":"2026-01-09","current":-0.101254,"twenty":-0.460447,"median":-0.284723,"eighty":-0.163023,"marketCap":6420182},{"date":"2026-01-16","current":-0.074044,"twenty":-0.457673,"median":-0.262988,"eighty":-0.151375,"marketCap":4694858},{"date":"2026-01-23","current":-0.056065,"twenty":-0.453513,"median":-0.243754,"eighty":-0.138341,"marketCap":3554888},{"date":"2026-01-30","current":-0.058573,"twenty":-0.449352,"median":-0.223866,"eighty":-0.121547,"marketCap":3713923},{"date":"2026-02-06","current":-0.042554,"twenty":-0.442879,"median":-0.192195,"eighty":-0.107345,"marketCap":2698240},{"date":"2026-02-13","current":-0.048688,"twenty":-0.435021,"median":-0.182701,"eighty":-0.093848,"marketCap":3087140},{"date":"2026-02-20","current":-0.048657,"twenty":-0.431486,"median":-0.176899,"eighty":-0.077306,"marketCap":3214676},{"date":"2026-02-27","current":-0.046857,"twenty":-0.428606,"median":-0.174834,"eighty":-0.060466,"marketCap":3095731},{"date":"2026-03-06","current":-0.040376,"twenty":-0.424799,"median":-0.173681,"eighty":-0.05647,"marketCap":2667530},{"date":"2026-03-13","current":-0.029045,"twenty":-0.422077,"median":-0.17085,"eighty":-0.050499,"marketCap":1918972},{"date":"2026-03-20","current":-0.028085,"twenty":-0.419765,"median":-0.170682,"eighty":-0.048484,"marketCap":1855535},{"date":"2026-03-27","current":-0.034166,"twenty":-0.417079,"median":-0.169454,"eighty":-0.047319,"marketCap":2257270},{"date":"2026-04-02","current":-0.035336,"twenty":-0.413827,"median":-0.167383,"eighty":-0.04606,"marketCap":2334602},{"date":"2026-04-10","current":-0.031762,"twenty":-0.406872,"median":-0.16427,"eighty":-0.043866,"marketCap":2098425},{"date":"2026-04-17","current":-0.033628,"twenty":-0.399911,"median":-0.155654,"eighty":-0.041322,"marketCap":2221738},{"date":"2026-04-24","current":-0.036697,"twenty":-0.399457,"median":-0.149858,"eighty":-0.040438,"marketCap":2424475},{"date":"2026-05-01","current":-0.032141,"twenty":-0.39557,"median":-0.138149,"eighty":-0.039889,"marketCap":2123505},{"date":"2026-05-08","current":-0.029421,"twenty":-0.386441,"median":-0.123469,"eighty":-0.037064,"marketCap":1943760},{"date":"2026-05-15","current":-0.023125,"twenty":-0.382964,"median":-0.117367,"eighty":-0.035899,"marketCap":1527837},{"date":"2026-05-22","current":-0.078772,"twenty":-0.376009,"median":-0.107725,"eighty":-0.036443,"marketCap":1446323},{"date":"2026-05-29","current":-0.077406,"twenty":-0.376009,"median":-0.101254,"eighty":-0.036697,"marketCap":1421242},{"date":"2026-06-05","current":-0.075584,"twenty":-0.369488,"median":-0.094421,"eighty":-0.037013,"marketCap":1387801},{"date":"2026-06-12","current":-0.110645,"twenty":-0.369488,"median":-0.091369,"eighty":-0.037013,"marketCap":2031540},{"date":"2026-06-18","current":-0.077861,"twenty":-0.359056,"median":-0.091369,"eighty":-0.037215,"marketCap":1429602},{"date":"2026-06-26","current":-0.068755,"twenty":-0.347754,"median":-0.088611,"eighty":-0.037494,"marketCap":1262397},{"date":"2026-07-02","current":-0.178687,"twenty":-0.344276,"median":-0.088611,"eighty":-0.038576,"marketCap":3280854},{"date":"2026-07-10","current":-0.220877,"twenty":-0.343407,"median":-0.091369,"eighty":-0.03962,"marketCap":4055500},{"date":"2026-07-17","current":-0.1973,"twenty":-0.335582,"median":-0.096459,"eighty":-0.039946,"marketCap":3622609},{"date":"2026-07-24","current":-0.179928,"twenty":-0.32515,"median":-0.101254,"eighty":-0.040156,"marketCap":3303637},{"date":"2026-07-31","current":-0.129051,"twenty":-0.321672,"median":-0.106776,"eighty":-0.040305,"marketCap":2369505},{"date":"2026-08-07","current":-0.16876,"twenty":-0.316456,"median":-0.111872,"eighty":-0.040388,"marketCap":3098584},{"date":"2026-08-14","current":-0.151387,"twenty":-0.306023,"median":-0.120497,"eighty":-0.04047,"marketCap":2779612},{"date":"2026-08-21","current":-0.136497,"twenty":-0.295156,"median":-0.123158,"eighty":-0.040781,"marketCap":2506208}],"updateTime":1787642158588},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPCB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624873554","title":"Propanc Biopharma plans 1-for-10 to 1-for-30 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2624873554","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624873554?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:41","pubTimestamp":1775000465,"startTime":"0","endTime":"0","summary":"Propanc Biopharma board adopted resolutions March 16, 2026, later enacted via shareholder written consent.Plan calls for restricted stock grants totaling 30 million shares to officers, directors, service providers.Board authorized reverse stock split in range 1-for-10 to 1-for-30.Reverse split expected to cut common shares outstanding to about 2.1 million to 0.7 million from about 20.9 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL53XP0S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621306094","title":"Propanc Biopharma signs multi-year collaboration with Spanish universities","url":"https://stock-news.laohu8.com/highlight/detail?id=2621306094","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621306094?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:11","pubTimestamp":1774357879,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced that a multi-year joint research collaboration agreement has been established with the Universities of Jaen and ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-signs-multi-year-collaboration-with-spanish-universities-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-signs-multi-year-collaboration-with-spanish-universities-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621620830","title":"Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration With the Universities of JaÉN and Granada, Spain","url":"https://stock-news.laohu8.com/highlight/detail?id=2621620830","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621620830?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:45","pubTimestamp":1774356300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUA7CK3TL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620782517","title":"Propanc Biopharma Inc. Files Draft Information Statement on Form PRE 14C","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782517","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620782517?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:02","pubTimestamp":1774000956,"startTime":"0","endTime":"0","summary":"Propanc Biopharma shareholders authorized the issuance of restricted common stock to officers, directors and service providers, including 7 million shares to James Nathanielsz.The authorization includes 2 million shares each to Jeannine Kingsley and VivoPharm.Additional issuances include 2.5 million shares each to Sylva International and Brunson Chandler & Jones.Shareholders also authorized a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-30.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Mar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL5Jb2b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618329881","title":"Propanc Biopharma Inc - Advancing Prp for Clinical Development in Pancreatic and Ovarian Cancers as Initial Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2618329881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618329881?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:47","pubTimestamp":1773319665,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nFWN4000OL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618132981","title":"Propanc Biopharma Inc - Prp Demonstrates Over 85% Tumor Growth Inhibition in Preclinical Pancreatic Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2618132981","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618132981?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:47","pubTimestamp":1773319665,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nFWN4000OL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618132679","title":"Propanc Biopharma Inc - Phase 1B First-in-Human Trials for Prp Set for 2026; $100 Mln Facility in Place","url":"https://stock-news.laohu8.com/highlight/detail?id=2618132679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618132679?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:47","pubTimestamp":1773319665,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nFWN4000OL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618604953","title":"Propanc Biopharma executes service agreement with FyoniBio","url":"https://stock-news.laohu8.com/highlight/detail?id=2618604953","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618604953?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:51","pubTimestamp":1773147078,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced that management has executed a service agreement with FyoniBio, a German Contract Development Organization, CDO,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-executes-service-agreement-with-fyonibio-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-executes-service-agreement-with-fyonibio-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618958268","title":"Propanc Biopharma signs service agreement with FyoniBio for LC-MS pharmacokinetics assay validation","url":"https://stock-news.laohu8.com/highlight/detail?id=2618958268","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618958268?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:46","pubTimestamp":1773146773,"startTime":"0","endTime":"0","summary":"Propanc Biopharma signed a service agreement with FyoniBio to establish and validate an LC-MS pharmacokinetics assay. The assay is intended to quantify PRP and its analytes in human serum during a Phase 1b first-in-human study in advanced solid-tumor patients. Propanc said the method aims for a maximum sensitivity of at least 0.1g/mL.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL2V1fhb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014039.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","LU0314104364.USD","NDAQ","BK4585","LU2210149790.SGD","SG9999014005.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","PPCB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618451958","title":"Propanc Biopharma Executes Service Agreement With Fyonibio to Establish & Validate Pharmacokinetics Assay for Phase 1B First-in-Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2618451958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618451958?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:45","pubTimestamp":1773146700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA7K4CV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616732599","title":"Propanc Biopharma highlights potential of lead asset PRP","url":"https://stock-news.laohu8.com/highlight/detail?id=2616732599","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616732599?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:59","pubTimestamp":1772546377,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) highlights the potential of its lead asset, PRP, as a novel therapeutic approach to the treatment and prevention of metast...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-highlights-potential-of-lead-asset-prp-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-highlights-potential-of-lead-asset-prp-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616323736","title":"BRIEF-Propanc Biopharma’S Lead Asset Prp Shows >85% Tumor Growth Inhibition In Preclinical Pancreatic Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2616323736","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616323736?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:48","pubTimestamp":1772545702,"startTime":"0","endTime":"0","summary":"BRIEF-Propanc Biopharma’S Lead Asset Prp Shows >85% Tumor Growth Inhibition In Preclinical Pancreatic ModelsMarch 3 (Reuters) - Propanc Biopharma Inc PPCB.O:PROPANC BIOPHARMA’S LEAD ASSET PRP SHOWS >8","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR19C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616785323","title":"Propanc Biopharma Inc: Gearing up for a Phase 1B First-in-Human Trial in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616785323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616785323?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:47","pubTimestamp":1772545623,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR19C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616323783","title":"Propanc Biopharma’s Lead Asset PRP Shows >85% TUMOR GROWTH INHIBITION IN PRECLINICAL PANCREATIC MODELS","url":"https://stock-news.laohu8.com/highlight/detail?id=2616323783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616323783?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:47","pubTimestamp":1772545623,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR19C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616273323","title":"Propanc Biopharma Plans 2026 Phase 1b First-in-Human Trial for PRP in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2616273323","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616273323?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:45","pubTimestamp":1772545519,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. announced plans to initiate a Phase 1b first-in-human clinical trial in 2026 evaluating its investigational intravenous proenzyme therapy PRP  in approximately 30 to 40 patients with advanced solid tumors. The company also reported preclinical findings in pancreatic cancer models showing more than 85% tumor growth inhibition. The Phase 1b trial results have not yet been presented and are expected to be generated in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL2CLbBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BGHQF748.EUR","PPCB","IE00BKPKM429.USD","LU2210149790.SGD","LU0314104364.USD","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014039.USD","BK4585","LU2210150020.SGD","BK4139","BK4112","SG9999014021.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614807258","title":"Propanc Biopharma Names Ralf Brant to Board as Julian Kenyon Retires","url":"https://stock-news.laohu8.com/highlight/detail?id=2614807258","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614807258?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:20","pubTimestamp":1772144443,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. said board member Dr. Julian Kenyon retired and stepped down effective Feb. 20, 2026, to focus on personal and family life, and will continue as a medical advisor. The company appointed Dr. Ralf Brant to fill the board vacancy, serving until removal or resignation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL6l05bX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":56,"code":"91000000","status":"200"}]}}